Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

148 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Factors influencing agreement of breast cancer luminal molecular subtype by Ki67 labeling index between core needle biopsy and surgical resection specimens.
Tendl-Schulz KA, Rössler F, Wimmer P, Heber UM, Mittlböck M, Kozakowski N, Pinker K, Bartsch R, Dubsky P, Fitzal F, Filipits M, Eckel FC, Langthaler EM, Steger G, Gnant M, Singer CF, Helbich TH, Bago-Horvath Z. Tendl-Schulz KA, et al. Among authors: mittlbock m. Virchows Arch. 2020 Oct;477(4):545-555. doi: 10.1007/s00428-020-02818-4. Epub 2020 May 7. Virchows Arch. 2020. PMID: 32383007 Free PMC article.
Do we need HER-2/neu testing for all patients with primary breast carcinoma?
Taucher S, Rudas M, Mader RM, Gnant M, Dubsky P, Bachleitner T, Roka S, Fitzal F, Kandioler D, Sporn E, Friedl J, Mittlböck M, Jakesz R. Taucher S, et al. Among authors: mittlbock m. Cancer. 2003 Dec 15;98(12):2547-53. doi: 10.1002/cncr.11828. Cancer. 2003. PMID: 14669272 Free article.
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.
Gnant M, Mlineritsch B, Luschin-Ebengreuth G, Kainberger F, Kässmann H, Piswanger-Sölkner JC, Seifert M, Ploner F, Menzel C, Dubsky P, Fitzal F, Bjelic-Radisic V, Steger G, Greil R, Marth C, Kubista E, Samonigg H, Wohlmuth P, Mittlböck M, Jakesz R; Austrian Breast and Colorectal Cancer Study Group (ABCSG). Gnant M, et al. Among authors: mittlbock m. Lancet Oncol. 2008 Sep;9(9):840-9. doi: 10.1016/S1470-2045(08)70204-3. Epub 2008 Aug 19. Lancet Oncol. 2008. PMID: 18718815 Clinical Trial.
• Pancho trial (p53-adapted neoadjuvant chemotherapy for resectable esophageal cancer) completed-mutation rate of the marker higher than expected.
Kappel-Latif S, Zacherl J, Hejna M, Westerhoff M, Tamandl D, Ba-Ssalamah A, Mittlböck M, Wolf B, Wrba F, Kührer I, Pluschnig U, Schoppmann SF, Függer R, Zwrtek R, Glaser K, Karner J, Längle F, Wenzl E, Roka R, Öfner D, Tschmelitsch J, Hold M, Keil F, Gnant M, Kandioler D; Pancho trialists and for the Medical University of Vienna p53research group. Kappel-Latif S, et al. Among authors: mittlbock m. Eur Surg. 2018;50(4):160-166. doi: 10.1007/s10353-018-0527-z. Epub 2018 Jun 11. Eur Surg. 2018. PMID: 30559831 Free PMC article.
Postoperative CMF Does Not Ameliorate Poor Outcomes in Women With Residual Invasive Breast Cancer After Neoadjuvant Epirubicin/Docetaxel Chemotherapy.
Promberger R, Dubsky P, Mittlböck M, Ott J, Singer C, Seemann R, Exner R, Panhofer P, Steger G, Bergen E, Gnant M, Jakesz R, Bago-Horvath Z, Rudas M, Bartsch R. Promberger R, et al. Among authors: mittlbock m. Clin Breast Cancer. 2015 Dec;15(6):505-11. doi: 10.1016/j.clbc.2015.06.007. Epub 2015 Jun 18. Clin Breast Cancer. 2015. PMID: 26195436
148 results